Partial response in a patient with skeletal and hepatic metastases following resected pancreatic cancer to the novel cell therapy SL-28: a case report
Tetz V. Kardava K. Shulenbayev O. Vecherkovskaya M. Khodadadi-Jamayran A. Tsirigos A. Tetz G.
2025Frontiers Media SA
Frontiers in Oncology
2025#15
Pancreatic cancer is a deadly and highly metastatic malignancy; the liver is the most frequent site of metastasis (70-80%), however, bone metastases are rare, occurring in approximately 5% of cases. Currently, there are no documented reports of effective responses to therapy for bone metastases, especially in the context of cell-based treatments. Here, we report the first case of a partial response according to RECIST v1.1, with a reduction in size and dissolution of liver and bone metastases from pancreatic cancer, for the novel cell therapy, SL-28, under the expanded access pathway (NCT06872489). SL-28 (Leukocyte-Tells) is a novel cell therapy that uses allogeneic leukocytes, whose anticancer activity is increased ex vivo using the recently discovered Universal Receptive System. A 79-year-old female, staged T4N0M1 after distal pancreatectomy with splenectomy, developed liver and bone metastases that were unresponsive to chemotherapy. A partial response was achieved in the third month of monotherapy SL-28 with partial disappearance of the metastasis in the right femur and a reduction in the metastatic bone mass in the left pubic bone, with over a 30% decrease in the sum of the diameters of the target lesions. In the liver, some metastatic lesions disappeared along with a shrinkage in the size of others. SL-28 therapy was well tolerated with no serious adverse effects. This is the first clinical case describing the partial response of a patient with liver and bone metastases after resection of pancreatic cancer to cell therapy using a novel type of cell therapy with SL-28. Copyright
bone metastasis , cell therapy , leucocyte-tells , liver metastasis , oncology , pancreatic cancer , SL-28 , TezR
Text of the article Перейти на текст статьи
Department of Structural Biology, Human Microbiology Instititue, New York, NY, United States
Private Hospital International Almaty, Almaty, Kazakhstan
Applied Bioinformatics Laboratories, Division of Advanced Research Technologies, New York University (NYU) School of Medicine, New York, NY, United States
Department of Pathology, New York University School of Medicine, New York, NY, United States
Department of Medicine, Division of Precision Medicine, NYU School of Medicine, New York, NY, United States
Tetz-Laboratories, New York, NY, United States
Second Life Therapeutics, New York, NY, United States
Department of Structural Biology
Private Hospital International Almaty
Applied Bioinformatics Laboratories
Department of Pathology
Department of Medicine
Tetz-Laboratories
Second Life Therapeutics
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026